Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1865

1.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

PMID:
15626746
[PubMed - indexed for MEDLINE]
Free Article
2.

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.

Cancer Res. 2005 Oct 15;65(20):9436-44.

PMID:
16230407
[PubMed - indexed for MEDLINE]
Free Article
3.

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.

PMID:
12483533
[PubMed - indexed for MEDLINE]
Free Article
4.
6.

Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.

Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.

Eur J Haematol. 2004 Apr;72(4):231-8.

PMID:
15089759
[PubMed - indexed for MEDLINE]
7.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

PMID:
15256422
[PubMed - indexed for MEDLINE]
Free Article
8.

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Chu S, Holtz M, Gupta M, Bhatia R.

Blood. 2004 Apr 15;103(8):3167-74. Epub 2003 Dec 11.

PMID:
15070699
[PubMed - indexed for MEDLINE]
Free Article
9.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
[PubMed - indexed for MEDLINE]
10.

Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.

Mayerhofer M, Florian S, Krauth MT, Aichberger KJ, Bilban M, Marculescu R, Printz D, Fritsch G, Wagner O, Selzer E, Sperr WR, Valent P, Sillaber C.

Cancer Res. 2004 May 1;64(9):3148-54.

PMID:
15126353
[PubMed - indexed for MEDLINE]
Free Article
11.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

PMID:
19240172
[PubMed - indexed for MEDLINE]
Free Article
12.

Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells.

Li QF, Huang WR, Duan HF, Wang H, Wu CT, Wang LS.

Oncogene. 2007 Dec 13;26(57):7904-8. Epub 2007 Jun 18.

PMID:
17599053
[PubMed - indexed for MEDLINE]
14.

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE.

Blood. 2003 Sep 15;102(6):2236-9. Epub 2003 May 15.

PMID:
12750174
[PubMed - indexed for MEDLINE]
Free Article
15.

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.

J Biol Chem. 2004 Aug 13;279(33):34227-39. Epub 2004 Jun 2.

PMID:
15175350
[PubMed - indexed for MEDLINE]
Free Article
16.

BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.

Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F.

Int J Oncol. 2011 Sep;39(3):585-91. doi: 10.3892/ijo.2011.1062. Epub 2011 Jun 1.

PMID:
21637917
[PubMed - indexed for MEDLINE]
17.

BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.

Cancer Res. 2007 Jun 1;67(11):5489-97.

PMID:
17545631
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.

Oncogene. 2002 Nov 21;21(53):8075-88.

PMID:
12444544
[PubMed - indexed for MEDLINE]
Free Article
20.

Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.

Rapozzi V, Cogoi S, Xodo LE.

Mol Cancer Ther. 2006 Jul;5(7):1683-92.

PMID:
16891454
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk